CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida

When small biotech Capsida launched just a few months ago, it hit the scene with backing from drug giant AbbVie to chase AAV-delivered drugs for …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR Ther­a­peu­tics takes a swing at ALS gene edit­ing in dis­cov­ery deal with AAV up­start Cap­si­da